• Skip to main content
  • Skip to footer

PeDRA

Pediatric Dermatology Research Alliance

  • DONATE
  • Join PeDRA
  • Login
MENUMENU
  • Contact Us
  • For Patients & Families
        • Patient Support
        • Patient Education
        • Community Spotlight
        • Play Eczema Counts Now!
        • Patient Advisory Committee
        • Find a Pediatric Dermatologist (from SPD)
        • Awards Program
        • Parents, advocates, and patients over the age of 18 with a direct connection or significant interest in childhood skin disease or pediatric dermatology research are encouraged to join the PeDRA network for free as Community Members.

          Apply Now!

  • Education and Events
        • Virtual Education
        • SPD/PeDRA Journal Club
        • PeDRA Pearls Podcast
        • Mentorship Program
        • 2023 Annual Conference
        • 2023 Dash for Discovery Fun Run/Walk
        • Early Investigator Support
        • Play Eczema Counts Now!
        • Events Calendar
        • Explore our educational catalog!

  • Research
        • Grants and Fellowships
        • Resources for Researchers
        • Survey Application
        • Study Application
        • Research Areas
        • Publications
        • PeDRA EDI Corner
        • View all open funding opportunities!

  • About
        • Mission, Vision, and Core Values
        • Leadership & Staff
        • Annual Reports & Financials
        • Awards Program
        • News Archive
        • Our Supporters
        • Our Membership
        • Member Spotlight
        • Our Committees
        • Getting to Know You
        • It’s Membership Renewal Time – Renew today!

  • Member Login

Needle-free delivery of intralesional triamcinolone for pediatric alopecia areata: a pilot study of patient tolerability

April 6, 2022 By Katherine Devenport


Principal Investigator:

Sonal Shah, MD
University Hospitals Cleveland Medical Center
Case Western Reserve University

Overview:

Alopecia areata (AA) is a type of hair loss that affects both adults and children. It may be limited to a few spots on the scalp or lead to hair loss across the whole body. AA has often been inappropriately considered a cosmetic condition; however, it can cause significant emotional and psychosocial distress. This can negatively impact the quality of life in affected children. Currently, there are no FDA-approved treatments for this disease. However, we do know that injecting steroids into the areas of hair loss can lead to regrowth. Unfortunately, the use of needles can be scary and painful for children, and many are unable to tolerate this treatment option. We aim to study the tolerability and effectiveness of a novel medical device that can deliver medication into the skin without the use of a needle.

Status:

This project was funded by a 2021 PeDRA Research Grant.

Filed Under: Hair Disorders

Footer

  • Our Membership
  • For Patients
  • For Researchers
  • Governance Policies
  • Financial Conflict of Interest Policy
  • Jobs at PeDRA
  • Facebook
  • Instagram
  • LinkedIn
  • Twitter
  • YouTube
Sign up to receive emails from PeDRA

Four Star Charity Navigator

Join PeDRA
Donate

Copyright © 2023 · Pediatric Dermatology Research Alliance (PeDRA) · All Rights Reserved. · Privacy Policy